Dmitry Balyasny’s PDL BioPharma, Inc. PDLI Stock Holding History

Dmitry Balyasny’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-18,200	Closed	-$54K	–	2395
2018 Q1	$54K	Buy	18,200 +5,300	+41%	+$14.5K	﹤0.01%	1860
2017 Q4	$35K	Buy	+12,900	New	+$39.6K	﹤0.01%	2021
2017 Q2	–	Sell	-100,017	Closed	-$227K	–	1969
2017 Q1	$227K	Buy	100,017 +56,717	+131%	+$125K	﹤0.01%	1461
2016 Q4	$92K	Buy	43,300 +11,968	+38%	+$33.4K	﹤0.01%	1318
2016 Q3	$105K	Sell	31,332 -14,100	-31%	-$44.8K	﹤0.01%	918
2016 Q2	$143K	Sell	45,432 -17,680	-28%	-$59K	﹤0.01%	1072
2016 Q1	$210K	Buy	63,112 +29,590	+88%	+$92.2K	﹤0.01%	1115
2015 Q4	$119K	Buy	+33,522	New	+$140K	﹤0.01%	1154

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Dmitry Balyasny's PDLI Position: Q2 2018 in Review

Dmitry Balyasny sold out of PDL BioPharma, Inc. (PDLI) in Q2 2018, closing a stake of 18,200 shares — an estimated $54K sold.

Dmitry Balyasny first reported a position in PDLI in Q4 2015 and held it in 8 quarters. The position peaked at $227K in Q1 2017. 163 funds tracked by Wall St. Rank hold PDLI as of Q2 2018.

Dmitry Balyasny reported no remaining PDL BioPharma, Inc. position as of Q2 2018 after selling out during the quarter.
Dmitry Balyasny sold 18,200 PDL BioPharma, Inc. shares in Q2 2018, an estimated $54K.
Dmitry Balyasny first reported a position in PDL BioPharma, Inc. in Q4 2015 and held it in 8 quarters.
Dmitry Balyasny's PDL BioPharma, Inc. position peaked at $227K in Q1 2017.
163 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2018.

Based on Balyasny Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.